Excess cases of prostate cancer and estimated overdiagnosis associated with PSA testing in East Anglia

被引:32
作者
Pashayan, N.
Powles, J.
Brown, C.
Duffy, S. W.
机构
[1] Inst Publ Hlth, Dept Publ Hlth & Primary Care, Cambridge CB2 2SR, England
[2] Eastern Canc Registrat & Informat Ctr, Cambridge CB2 2QQ, England
[3] Canc Res UK, Ctr Epidemiol Math & Stat, Wolfson Inst Prevent Med, London EC1M 6BQ, England
关键词
excess cases; overdiagnosis; PSA; prostate cancer;
D O I
10.1038/sj.bjc.6603246
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study aimed to estimate the extent of 'overdiagnosis' of prostate cancer attributable to prostate-specific antigen (PSA) testing in the Cambridge area between 1996 and 2002. Overdiagnosis was defined conceptually as detection of prostate cancer through PSA testing that otherwise would not have been diagnosed within the patient's lifetime. Records of PSA tests in Addenbrookes Hospital were linked to prostate cancer registrations by NHS number. Differences in prostate cancer registration rates between those receiving and not receiving prediagnosis PSA tests were calculated. The proportion of men aged 40 years or over with a prediagnosis PSA test increased from 1.4 to 5.2% from 1996 to 2002. The rate of diagnosis of prostate cancer was 45% higher (rate ratios (RR) = 1.45, 95% confidence intervals (CI) 1.02-2.07) in men with a history of prediagnosis PSA testing. Assuming average lead times of 5 to 10 years, 40-64% of the PSA-detected cases were estimated to be overdiagnosed. In East Anglia, from 1996 to 2000, a 1.6% excess of cases was associated with PSA testing (around a quarter of the 5.3% excess incidence cases observed in East Anglia from 1996 to 2000). Further quantification of the overdiagnosis will result from continued surveillance and from linkage of incidence to testing in other hospitals.
引用
收藏
页码:401 / 405
页数:5
相关论文
共 17 条
  • [1] Lead-time in prostate cancer screening (Finland)
    Auvinen, A
    Määttänen, L
    Stenman, UH
    Tammela, T
    Rannikko, S
    Aro, J
    Juusela, H
    Hakama, M
    [J]. CANCER CAUSES & CONTROL, 2002, 13 (03) : 279 - 285
  • [2] Determining overdiagnosis by screening with DRE/TRUS or PSA (Florence pilot studies, 1991-1994)
    Ciatto, S
    Gervasi, G
    Bonardi, R
    Frullini, P
    Zendron, P
    Lombardi, C
    Crocetti, E
    Zappa, M
    [J]. EUROPEAN JOURNAL OF CANCER, 2005, 41 (03) : 411 - 415
  • [3] Lead times and overdetection due to prostate-specific antigen screening:: Estimates from the European randomized study of screening for prostate cancer
    Draisma, G
    Boer, R
    Otto, SJ
    van der Cruijsen, IW
    Damhuis, RAM
    Schröder, FH
    de Koning, HJ
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (12) : 868 - 878
  • [4] DUFFY SW, 2001, QUANTITATIVE METHODS
  • [5] The incidence of prostate cancer in men with prostate specific antigen greater than 4.0 ng/ml: A randomized study of 6 versus 12 core transperineal prostate biopsy
    Emiliozzi, P
    Scarpone, P
    DePaula, F
    Pizzo, M
    Federico, G
    Pansadoro, A
    Martini, M
    Pansadoro, V
    [J]. JOURNAL OF UROLOGY, 2004, 171 (01) : 197 - 199
  • [6] Etzioni R, 2002, J NATL CANCER I, V94, P981
  • [7] A PROSPECTIVE EVALUATION OF PLASMA PROSTATE-SPECIFIC ANTIGEN FOR DETECTION OF PROSTATIC-CANCER
    GANN, PH
    HENNEKENS, CH
    STAMPFER, MJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (04): : 289 - 294
  • [8] Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden
    Hugosson, J
    Aus, G
    Becker, C
    Carlsson, S
    Eriksson, H
    Lilja, H
    Lodding, P
    Tibblin, G
    [J]. BJU INTERNATIONAL, 2000, 85 (09) : 1078 - 1084
  • [9] Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma
    Hugosson, J
    Aus, G
    Lilja, H
    Lodding, P
    Pihl, CG
    [J]. CANCER, 2004, 100 (07) : 1397 - 1405
  • [10] McGregor M, 1998, CAN MED ASSOC J, V159, P1368